{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:49:40Z","timestamp":1768409380796,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jcf.2022.04.018","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T16:59:19Z","timestamp":1652115559000},"page":"741-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-1891","authenticated-orcid":false,"given":"Miguel Angel","family":"Martinez-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Mar\u00eda","family":"Sierra-P\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.04.018_bib0001","article-title":"Cystic fibrosis: quality of life and radiological monitoring","author":"Diab C\u00e1ceres","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0002","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jcf.2019.11.003","article-title":"The genetics and genomics of cystic fibrosis","volume":"19","author":"Sharma","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.04.018_bib0003","article-title":"Effect of sex differences on computed tomography findings in adults with cystic fibrosis: a multicenter study","author":"Diab C\u00e1ceres","year":"2021","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.jcf.2022.04.018_bib0004","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","article-title":"Recommendations for the classification of diseases as CFTR-related disorders","volume":"10","author":"Bombieri","year":"2011","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2022.04.018_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00558-2020","article-title":"Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population","volume":"56","author":"\u00c7olak","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.arbr.2020.11.010","article-title":"RIBRON: The Spanish online bronchiectasis registry. Characterization of the first 1912 patients","volume":"57","author":"Martinez-Garc\u00eda","year":"2021","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"8","key":"10.1016\/j.jcf.2022.04.018_bib0007","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/resp.12832","article-title":"Aetiology of bronchiectasis in adults: A systematic literature review","volume":"21","author":"Gao","year":"2016","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.jcf.2022.04.018_bib0008","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00069007","article-title":"Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms","volume":"31","author":"Fuschillo","year":"2008","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2022.04.018_bib0009","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.arbr.2020.06.003","article-title":"Repeteability of circulating eosinophil measures and inhaled corticosteroids effect in bronchiectasis. a post hoc analysis of a randomized clinical trial","volume":"56","author":"Martinez-Garcia","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.jcf.2022.04.018_bib0010","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterisation of eosinophilic bronchiectasis: a European multicohort study","author":"Shoemark","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.04.018_bib0011","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.arbres.2021.08.001","article-title":"Bronchiectasis and eosinophils","volume":"57","author":"Martinez-Garcia","year":"2021","journal-title":"Arch Bronconeumol."},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.arbr.2019.12.022","article-title":"C-reactive protein concentration in steady-state bronchiectasis: prognostic value of future severe exacerbations. Data from the spanish registry of bronchiectasis (RIBRON)","volume":"57","author":"Posadas","year":"2021","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.jcf.2022.04.018_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2017.04.009","article-title":"The heterogeneity of systemic inflammation in bronchiectasis","volume":"127","author":"Saleh","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.arbr.2019.04.014","article-title":"Look at the wood and not at the tree: the microbiome in chronic obstructive lung disease and cystic fibrosis","volume":"56","author":"Mons\u00f3","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"2","key":"10.1016\/j.jcf.2022.04.018_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2022.04.018_bib0016","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.arbres.2020.04.023","article-title":"Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease","volume":"56","author":"de la Rosa Carrillo","year":"2020","journal-title":"Arch Bronconeumol"},{"issue":"10","key":"10.1016\/j.jcf.2022.04.018_bib0017","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.arbr.2019.12.014","article-title":"The roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study","volume":"56","author":"Chen","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.jcf.2022.04.018_bib0018","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jcf.2022.04.018_bib0019","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.arbr.2020.03.015","article-title":"Bronchial infection due to pseudomonas aeruginosa in patients with cystic fibrosis diagnosed in neonatal screening","volume":"56","author":"R","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212468","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.04.018_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/thx.2003.020263","article-title":"Role of CFTR mutations in adult bronchiectasis","volume":"59","author":"King","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.04.018_bib0022a","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcf.2015.02.012","article-title":"Should diffuse bronchiectasis still be considered a CFTR-related disorder?","volume":"14","author":"Bergougnoux","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.04.018_bib0022b","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.0009-9163.2004.00265.x","article-title":"Bronchiectasis in adult patients: an expression of heterozyosity for CFTR gene mutations?","volume":"65","author":"Casals","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.jcf.2022.04.018_bib0023","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000484750","article-title":"CFTR gene mutation in adults with disseminated bronchiectasis","volume":"5","author":"Girodon","year":"1997","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jcf.2022.04.018_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0068-2019","article-title":"CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways","volume":"29","author":"Patel","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jcf.2022.04.018_bib0025","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1111\/j.1432-1033.2004.04204.x","article-title":"Effect of priming on activation and localization of phospholipase D-1 in human neutrophils","volume":"271","author":"Cadwallader","year":"2004","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jcf.2022.04.018_bib0026","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/biomedicines9101437","article-title":"Dysfunction in the cystic fibrosis transmembrane regulator in chronic obstructive pulmonary disease as a potential target for personalised medicine","volume":"9","author":"Carrasco-Hernandez","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcf.2022.04.018_bib0027","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1164\/rccm.202109-2064TR","article-title":"Cystic fibrosis transmembrane conductance regulator: roles in chronic obstructive pulmonary disease","volume":"205","author":"Dransfield","year":"2022","journal-title":"Am J Respir Crit Care Med Vol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0028","doi-asserted-by":"crossref","first-page":"L530","DOI":"10.1152\/ajplung.00039.2013","article-title":"Cigarette smoke and CFTR: implications in the pathogenesis of COPD","volume":"305","author":"Rab","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0029","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.arbres.2020.07.024","article-title":"Prevalence and determinants of COPD in Spain: EPISCAN II","volume":"57","author":"Soriano","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0030","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","author":"Adeloye","year":"2022","journal-title":"Labcet Resp Med"},{"issue":"4","key":"10.1016\/j.jcf.2022.04.018_bib0031","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.arbres.2019.06.016","article-title":"Assessment of induced sputum cellularity in COPD patients belonging to two different classes of air pollution exposure","volume":"56","author":"Dragonieri","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0032","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.arbres.2020.11.015","article-title":"Indoor radon exposure and COPD, synergic association? A multicentric, hospital-based case-control study in a radon-prone area","volume":"57","author":"Ruano-Ravina","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0033","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.arbres.2020.07.022","article-title":"HLA-DRB1 alleles are associated with COPD in a Latin American admixed population","volume":"57","author":"D\u00edaz-Pe\u00f1a","year":"2021","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"10.1016\/j.jcf.2022.04.018_bib0034","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.arbres.2019.03.001","article-title":"Scientific committee; participating sites and coordinators. Serum levels of Alpha1-antitrypsin and their relationship with COPD in the general Spanish population","volume":"56","author":"Janciauskiene","year":"2020","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"10.1016\/j.jcf.2022.04.018_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.arbres.2020.08.002","article-title":"GesEPOC 2021: one more step towards personalized treatment of COPD","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0036","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.arbres.2020.07.008","article-title":"Exacerbation syndrome in COPD: a paradigm shift","volume":"57","author":"Soler-Catalu\u00f1a","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0037","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.arbres.2021.01.025","article-title":"Implementation of an integrated care model for frequent-exacerbator COPD patients: a controlled prospective study","volume":"57","author":"Cos\u00edo","year":"2021","journal-title":"Arch Bronconeumol Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0038","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6567578","article-title":"Cigarette smoke-induced acquired dysfunction of cystic fibrosis transmembrane conductance regulator in the pathogenesis of chronic obstructive pulmonary disease","volume":"2018","author":"Shi","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jcf.2022.04.018_bib0039","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.11-192377","article-title":"Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration","volume":"26","author":"Clunes","year":"2012","journal-title":"Faseb J"},{"key":"10.1016\/j.jcf.2022.04.018_bib0040","doi-asserted-by":"crossref","first-page":"13655","DOI":"10.1038\/s41598-019-49544-9","article-title":"Cigarette smoke exposure induces retrograde trafficking of CFTR to the endoplasmic reticulum","volume":"9","author":"Marklew","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2022.04.018_bib0041","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/lary.23278","article-title":"Cystic fibrosis transmembrane conductance regulator modulation by the tobacco smoke toxin acrolein","volume":"122","author":"Alexander","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jcf.2022.04.018_bib0042","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1465-9921-15-69","article-title":"Accumulation of metals in GOLD4 COPD lungs is associated with decreased CFTR levels","volume":"15","author":"Hassan","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2022.04.018_bib0043","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4049\/jimmunol.1002850","article-title":"Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema","volume":"186","author":"Bodas","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0044","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12038-020-0013-1","article-title":"Effect of lentivirus-mediated CFTR overexpression on oxidative stress injury and inflammatory response in the lung tissue of COPD mouse model","author":"Xu","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.jcf.2022.04.018_bib0045","doi-asserted-by":"crossref","first-page":"C262","DOI":"10.1152\/ajpcell.00070.2005","article-title":"Oxidant stress suppresses CFTR expression","volume":"290","author":"Cantin","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.601438","article-title":"Cystic fibrosis lung disease in the aging population","volume":"12","author":"Kunzi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2022.04.018_bib0047","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/hmg\/4.4.635","article-title":"Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis","volume":"4","author":"Pignatti","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcf.2022.04.018_bib0048","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s004390100467","article-title":"CFTR gene mutations\u2013including three novel nucleotide substitutions\u2013and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease","volume":"108","author":"Tzetis","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.jcf.2022.04.018_bib0049","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.04.018_bib0050","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.04.018_bib0051","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.jcf.2022.04.018_bib0052","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.12.009","article-title":"Towards next generation therapies for cystic fibrosis: folding, function and pharmacology of CFTR","volume":"19","author":"Bose","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.04.018_bib0053","unstructured":"Clinical trials.gov [Last Access 24.04.2022]"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:46:57Z","timestamp":1761601617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1569199322001072"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.04.018","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}